India, March 31 -- BiomX Inc. (PHGE), a clinical-stage company focused on phage therapies that target specific pathogenic bacteria, announced Monday positive, topline safety and efficacy results from its Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis or DFO.
Following the successful Phase 2 readout of BX211, the company said it is planning for a Phase 2/3 trial, pending discussions and feedback from the U.S Food and Drug Administration.
In pre-market activity on the NYSE, BiomX shares were losing around 7 percent.
DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. BX211 is a phage treatment for the treatment of DFO asso...